Fig. 1From: Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s diseaseThe experimental design. Melatonin or saline was subcutaneously administered to 5- and 8-month-old male hTau mice 3 times per week for 5 months. The mice were subjected to tau pathology examination and miRNA profiling. N2a cells were treated with NC, miR-504-3p mimics, or miR-504-3p inhibitor in the absence or presence of melatonin or p39 and then subjected to functional and mechanistic studiesBack to article page